Back when I was a kid, food allergies seemed rare. I can’t remember any of my friends carrying around an EpiPen – and we used to eat spoonfuls of peanut butter like they were candy.
But now, fifteen million people in the U.S. are allergic to some type of food.
These allergies tend to range from specific food groups like shellfish to the broader categories of gluten and dairy. I’ve even heard of someone who is allergic to the pesticides they spray on fresh fruits and vegetables – not a food allergy per se, but it prevents them from eating a ton of produce!
Of those 15 million people, there is one allergy that plagues the majority of them – peanuts.
Peanut allergies have become so common that schools across the country are beginning to ban peanut butter and jelly sandwiches, ants on a log, Reese’s Peanut Butter Cups, you name it. Basically, anything containing peanuts or peanut products, which includes a ton of staple lunchbox stuffers for parents.
For those diagnosed with the common allergy, eating peanut products can produce anything from a scratchy throat to a deadly reaction. Some parents avoid feeding their kids peanut butter altogether for fear of the potential outcome.
But a new drug on its way to the Food and Drug Administration (FDA) could change all of that. And it’s more than just a medical innovation – this peanut allergy treatment could be your wallet’s latest breakthrough as well.
Here’s how…
How a Peanut Allergy Treatment Could Land You a Fast Double
Over the past few years, many companies have been trying to develop an FDA-approved treatment for peanut allergies.
DBV Technologies SA (NASDAQ: DBVT), for example, created an experimental arm patch. French multinational pharmaceutical company, Sanofi SA (NASDAQ: SNY), and biotechnology company, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), are in the process of developing their own drugs as well.
But if peanut allergy treatment was a race, then Aimmune Therapeutics Inc. (NASDAQ: AIMT) would be pulling ahead of the rest.
AIMT has developed the first biologic drug to treat peanut allergies, and it just won the recommendation of the Allergenic Products Advisory Committee (APAC).
The drug, set to be called Palforzia, is an oral powder that can be mixed in with food or swallowed as a pill. Once taken, it produces a daily dose of peanut protein that starts a small immune response in those with a peanut allergy. The idea is that the daily dose will eventually build the immune system’s tolerance to peanuts.
Now, the drug isn’t to be confused with a cure. It doesn’t make the allergy go away completely. But it does protect against exposures – something extremely important to those who could suffer deadly consequences if they come in contact with peanuts or peanut products.
The next step for the drug is the FDA. And while the APAC recommendation doesn’t guarantee FDA approval, the blessing of a regulatory advisory committee tends to hold a lot of weight with the Administration. So clearly, things are looking good for AIMT.
Special Feature: Thanks to something called Cannabis Lots, my data shows you could make $10,000 in a week… $12,325 in only 13 days… even $17,500 in just 24 hours. That’s the power of these Cannabis Lots – and as soon as you get started, you can see this obscene profit potential hit your account in just minutes. Take a look…
The pharmaceutical company’s CEO, Jayson Dallas, knows the importance – and positive implications – of the new drug. Of those with a diagnosed peanut allergy, he said:
“There are over 1.6 million children and teens in the U.S., many of whom are anxiously waiting for an FDA-approved medicine that will provide them with an option beyond avoidance alone.”
Well, those 1.6 million people’s wait may just pay off by January 2020, when the FDA is set to make a final decision on Palforzia.
But you don’t have to wait that long. With options, you can profit off AIMT’s groundbreaking medication in no time.
The stock has fallen in recent days after shareholders took profits on the recommendation news, making option prices inexpensive – and providing the ideal entry point for a bullish option trade.
To see just how quick and lucrative a call trade can be, check out what my readers just did with TreeHouse Foods Inc. (NYSE: THS) …
On August 27, 2019, THS was trading around $49.29. And, just like AIMT, the stock was set to rise.
So, my readers bought a THS call option for $2.15, or $215 for control over 100 shares. Just as we expected, THS shot up after that. And on September 6, the stock was trading around $55.20.
My readers sold their call option for $6.10, taking home a whopping 183.72% profit in only 10 short days.
By harnessing the power of call options, you can take home a life-changing gain just like that on AIMT.
Good trading,
Tom Gentile
America’s #1 Pattern Trader
